Doctor Jil Billy Mamza

AstraZeneca, London (United Kingdom of Great Britain & Northern Ireland)

Membership: ESC Professional Member

Contributor content

$Clinical characteristics and treatment patterns of new users of dapagliflozin for heart failure with reduced ejection fraction: an observational study programme across 12 countries (EVOLUTION HF)$

Journal

Clinical characteristics and treatment patterns of new users of dapagliflozin for heart failure with reduced ejection fraction: an observational study programme across 12 countries (EVOLUTION HF)

28 October 2024

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources